Scarica l'app Stockscreener
20.43
5.64%
1.09
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
CorMedix Inc. (CRMD) Stock Price & News - Syfe
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc.TYRA - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc.TYRA - GlobeNewswire Inc.
Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history - Yahoo Finance UK
Tyra Biosciences, Inc. (TYRA) stock price, news, quote and history - Yahoo Finance Australia
Tyra Biosciences, Inc. (TYRA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Biotech fund group reports stake in Tyra Biosciences (NASDAQ: TYRA) — here’s how much of the company it holds - Stock Titan
Tyra Biosciences (Nasdaq:TYRA)Stock Analysis - simplywall.st
Press Releases about Tyra Biosciences, Inc.Common Stock (Nasdaq:TYRA) - FinancialContent
Tyra Biosciences (NASDAQ: TYRA) CEO lifts stake to 1,438,495 shares - Stock Titan
Stock grant lifts Tyra Biosciences (NASDAQ: TYRA) finance VP stake to 11,258 shares - Stock Titan
CFO adds shares in Tyra Biosciences (TYRA) via plan - Stock Titan
Tyra Biosciences (TYRA) investor uses capped warrants to reach 19.99% stake - Stock Titan
RA Capital buys $0.001-share warrants in Tyra Biosciences (TYRA) - Stock Titan
Investor group reports over 5% stake in Tyra Biosciences (TYRA) - Stock Titan
Tyra Announces $400M Pricing of Common Stock and Pre-Funded Warrants - TradingView
Elmet Group, Rum Group, Tyra Biosciences And Other Big Stocks Moving Higher On Monday - Benzinga
Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - PR Newswire
A biotech expects to raise about $400 million for drug development. Tyra priced the stock sale. - Stock Titan
Update: Tyra Bioscience Shares Rise After Pricing $400 Million Offering - Yahoo Finance
Latham & Watkins Advises Tyra on US$400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants - Latham & Watkins LLP
Tyra Bioscience Prices $400 Million Offering of Shares and Warrants - Yahoo Finance
Crude Oil Jumps 3%; Corning Shares Move Lower - benzinga.com
Tyra Biosciences (TYRA) director adds shares in open-market buy - Stock Titan
Tyra Biosciences Inc. (TYRA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc.TYRA - PR Newswire
Tyra Biosciences Inc. (TYRA) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Dabogratinib Shows Early Activity in FGFR3-Altered Low-Grade NMIBC - CancerNetwork
Cantor Fitzgerald reiterates Tyra Biosciences stock rating after trial data - Investing.com
Cantor Fitzgerald reiterates Tyra Biosciences stock rating after trial data By Investing.com - Investing.com Canada
Tyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBCSlideshow (NASDAQ:TYRA) 2026-09-10 - Seeking Alpha
A Quick Look at Today's Ratings for TYRA BIOSCIENCES, INC.(TYRA.US), With a Forecast Between $30 to $59 - Moomoo
H.C. Wainwright Maintains TYRA BIOSCIENCES, INC.(TYRA.US) With Buy Rating, Cuts Target Price to $30 - moomoo.com
Tyra Biosciences at 12th Annual Cantor Fitzgerald Global Healthcare Conference: oral drug push - Investing.com Canada
Tyra disappoints investors with bladder cancer data - BioPharma Dive
TYRA: Oral FGFR3 inhibitor shows robust efficacy and safety, advancing to phase III for MIBC - TradingView
Tyra Biosciences Tanks As IR NMIBC Data Disappoints: I'm Firmly On The Sidelines (TYRA) - Seeking Alpha
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Why Is Tyra Biosciences Stock Sinking Wednesday? - Benzinga
Balversa reversa? Tyra’s bladder cancer drug hits in phase II - BioWorld News
Tyra Biosciences reports 79% response rate for bladder cancer drug dabogratinib - Minichart
Tyra Biosciences (TYRA) Shares Plunge 22% as Bladder Cancer Drug Trial Falls Short - Blockonomi
TYRA: Oral dabogratinib at 60 mg shows strong efficacy and safety, advancing to phase III in NMIBC - TradingView
Why This Biotech Stock Just Plummeted To A 10-Month Low - Investor's Business Daily
Tyra reports 79% response rate in Phase 2 cancer trial - grafa.com
Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress - Barron's
Tyra Biosciences stock tumbles 30% on phase 2 trial results By Investing.com - Investing.com Australia
Tyra Biosciences shares plunge 30% after Phase 2 dabogratinib data - Yahoo Finance
Why is Tyra Biosciences stock plunging today? - Investing.com
Tyra Biosciences stock tumbles 30% on phase 2 trial results - investing.com
6.74%
4.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):